

Bactiguard strengthens licensing with Anders Göransson entering new role as Global Head of Licensing. Thomas von Koch appointed interim CEO

The Board of Bactiguard Holding AB (publ) (“Bactiguard”) today announces that current CEO Anders Göransson will step down as CEO to enter a new role as Global Head of Licensing and Executive Vice President. The Board has, in view of this, appointed the Chair of the Board Thomas von Koch as interim CEO. Vice Chair of the Board Christian Kinch assumes the role of non-executive Chair for the period during which Thomas von Koch is unable to be Chair due to the interim CEO position.

Anders Göransson joined Bactiguard in October 2021 with the objective to formulate a comprehensive long-term strategy and sharpen internal processes. Over the course of one and a half years with the company, these objectives have been accomplished. Bactiguard has a clear growth strategy and five well defined therapeutic areas. In addition, two long-term financial goals have been defined, to achieve revenues of 1 billion and an EBITDA of 400 MSEK by 2026. With the new growth-focused strategy in place, Bactiguard enters a new phase of the company’s development, to build both an even stronger license business and enter the US. Bactiguard is also on a transformation journey, from being a medical device company to a medtech business. This shift demands additional leadership skills to accelerate the journey, for instance from digital disruption and internationalization.

“Anders Göransson has been instrumental in kicking off the transformation of Bactiguard, laying the groundwork for our growth-focused strategy. As we enter the next phase of development, bolstering our licensing capabilities is paramount and I am glad to announce the appointment of Anders as our Global Head of Licensing, to strategize and drive Bactiguard’s new key growth area. The shift from being a medical device company to a full-fledged medtech company has only just begun,” states Thomas von Koch, interim CEO.

“I am looking forward to taking Bactiguard’s licensing business to the next level and being able to focus fully. With a clear growth strategy now in place, my full focus in this next phase will be to build a stronger Licensing team, as well as to intensify our efforts to go after the USD 80 billion market opportunity across our therapeutic areas,” states Anders Göransson, Global Head of Licensing.

All roles mentioned above are assumed with immediate effect. The search for a new CEO starts immediately.

This is information that Bactiguard Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below 2023-05-21, at 22:45 CEST.

For further information, please contact:
Nina Nornholm, Director Communications & IR, +46 708 550 356



About Bactiguard

Bactiguard is a global medtech company with a purpose to prevent infections. We provide safe, cost-effective, and easy-to-use infection prevention technology and solutions across five therapeutic areas – orthopedics, urology, intravascular/critical care, dental, and wound care.

Bactiguard's unique technology is based on a thin noble metal coating that prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard's solutions are biocompatible and make a positive impact by decreasing patient suffering, saving lives and healthcare resources. The solutions also fight antimicrobial resistance, one of the most serious threats to global health and modern medicine.

Bactiguard operates through license partnerships with leading global medtech companies, such as BD and Zimmer Biomet, differentiating their medical devices with our coating technology, and through the Bactiguard Infection Protection (BIP) product portfolio. BIP includes coated medical devices such as catheters and trauma implants, and wound care products and sutures.

Bactiguard is headquartered in Stockholm, has production in Sweden and Malaysia, and in total around 210 employees. Listed on Nasdaq Stockholm, the company reported revenues of 253.5 MSEK in 2022.

Read more on www.bactiguard.com

Follow Bactiguard on [LinkedIn](#)

